Amgen Inc. (NASDAQ:AMGN) Shares Sold by Auxier Asset Management

Auxier Asset Management reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 3.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,715 shares of the medical research company’s stock after selling 300 shares during the period. Auxier Asset Management’s holdings in Amgen were worth $2,723,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Transatlantique Private Wealth LLC grew its holdings in shares of Amgen by 15.3% in the second quarter. Transatlantique Private Wealth LLC now owns 3,469 shares of the medical research company’s stock valued at $1,084,000 after purchasing an additional 460 shares during the period. Summit Trail Advisors LLC boosted its holdings in Amgen by 4.5% in the 2nd quarter. Summit Trail Advisors LLC now owns 5,389 shares of the medical research company’s stock valued at $1,684,000 after purchasing an additional 231 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Amgen by 6.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 625,305 shares of the medical research company’s stock valued at $195,377,000 after buying an additional 36,019 shares during the period. Sei Investments Co. grew its stake in shares of Amgen by 1.4% in the 2nd quarter. Sei Investments Co. now owns 379,688 shares of the medical research company’s stock valued at $118,627,000 after buying an additional 5,264 shares during the period. Finally, Pacer Advisors Inc. increased its holdings in shares of Amgen by 8.9% during the 2nd quarter. Pacer Advisors Inc. now owns 74,039 shares of the medical research company’s stock worth $23,133,000 after buying an additional 6,048 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AMGN has been the topic of a number of recent analyst reports. Bank of America upped their price objective on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Wells Fargo & Company cut shares of Amgen from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $320.00 to $335.00 in a research report on Wednesday, August 7th. TD Cowen upped their price objective on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $305.00 target price (down previously from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Finally, Oppenheimer restated an “outperform” rating and set a $380.00 target price on shares of Amgen in a report on Wednesday, August 7th. Eleven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $327.28.

Amgen Price Performance

Shares of AMGN opened at $337.38 on Friday. The firm has a market capitalization of $180.98 billion, a price-to-earnings ratio of 48.20, a PEG ratio of 2.93 and a beta of 0.61. The firm’s fifty day simple moving average is $329.57 and its 200-day simple moving average is $305.62. Amgen Inc. has a twelve month low of $249.70 and a twelve month high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The business had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The firm’s quarterly revenue was up 20.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.00 earnings per share. Equities analysts forecast that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were paid a $2.25 dividend. The ex-dividend date was Friday, August 16th. This represents a $9.00 annualized dividend and a yield of 2.67%. Amgen’s dividend payout ratio is currently 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.